PYC Therapeutics Ltd (ASX: PYC) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

PYC Therapeutics Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $1.26 billion
P/E Ratio N/A
Dividend Yield 0.00%
Shares Outstanding 983.26 million
Earnings per share -0.083
Dividend per share N/A
Year To Date Return -20.80%
Earnings Yield N/A
Franking -
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

  • PYC Therapeutics Ltd (ASX: PYC)
    Latest News

    A worried man holds his head and look at his computer.
    Share Fallers

    Why Arcadium Lithium, IAG, PYC Therapeutics, and Zip shares are falling today

    These ASX shares are starting the year in the red.

    Read more »

    A medical researcher works on a bichip, indicating share price movement in ASX tech companies
    Share Market News

    Why is the PYC Therapeutics share price up 170% in a year?

    The PYC Therapeutics share price has risen 170% this year and 13% this month, following promising results in the development…

    Read more »

    row of piggy banks with large one receiving injection representing rising Immutep share price
    Share Market News

    Why the PYC Therapeutics (ASX:PYC) share price is up 11% today

    The PYC Therapeutics share price is higher today after the company announced that it has added another drug to its…

    Read more »

    A group of three scientists talking excitedly while working in a lab on a diabetes test developed by Proteomics International Laboratories which is an ASX share tipped to explode by Alto Capital
    Share Market News

    Why the PYC Therapeutics (ASX:PYC) share price is up 9% today

    The PYC Therapeutics share price is up 9% today following a promising ASX announcement on the effectiveness of its lead…

    Read more »

    a woman
    ⏸️ Investing

    Why Phylogica Limited soared 80% today

    Phylogica Limited (ASX:PYC) reports some excellent news

    Read more »

    PYC ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
    YesNo

    About PYC Therapeutics Ltd

    PYC Therapeutics Ltd. is a drug-development company, which offers a new generation of RNA therapeutics to meet unmet need in disease. It develops intracellular biological therapeutics including its own preclinical oncology payloads, using its proprietary cell Functional Penetrating Phylomers. The company was founded by Richmond Miles Hopkins and Paul Michael Watt on October 9, 2001 and is headquartered in Nedlands, Australia.

    PYC Share Price History Data provided by Morningstar.

    Data provided by Morningstar.
    Date Close Change % Change Volume Open High Low
    17 Apr 2026 $1.28 $0.05 4.07% 1,406,322 $1.23 $1.31 $1.22
    16 Apr 2026 $1.23 $0.02 1.65% 864,928 $1.23 $1.25 $1.20
    15 Apr 2026 $1.21 $0.06 5.22% 1,287,849 $1.15 $1.27 $1.15
    14 Apr 2026 $1.15 $0.00 0.00% 944,225 $1.15 $1.19 $1.15
    13 Apr 2026 $1.15 $-0.03 -2.55% 956,818 $1.17 $1.17 $1.13
    10 Apr 2026 $1.18 $0.06 5.38% 822,959 $1.20 $1.20 $1.13
    09 Apr 2026 $1.12 $-0.04 -3.45% 736,869 $1.20 $1.20 $1.10
    08 Apr 2026 $1.16 $0.09 8.45% 822,836 $1.10 $1.18 $1.10
    07 Apr 2026 $1.07 $-0.05 -4.48% 576,349 $1.11 $1.12 $1.05
    02 Apr 2026 $1.12 $-0.05 -4.29% 1,065,174 $1.18 $1.18 $1.09
    01 Apr 2026 $1.17 $0.06 5.45% 2,483,883 $1.16 $1.21 $1.13
    31 Mar 2026 $1.10 $-0.01 -0.90% 906,838 $1.15 $1.16 $1.07
    30 Mar 2026 $1.12 $0.01 0.91% 1,050,058 $1.12 $1.14 $1.08
    27 Mar 2026 $1.10 $-0.07 -5.98% 2,367,850 $1.19 $1.19 $1.09
    26 Mar 2026 $1.17 $-0.05 -4.10% 961,087 $1.25 $1.25 $1.15
    25 Mar 2026 $1.22 $0.04 3.39% 2,358,979 $1.13 $1.24 $1.13
    24 Mar 2026 $1.18 $-0.02 -1.67% 1,437,416 $1.23 $1.26 $1.16
    23 Mar 2026 $1.20 $-0.13 -9.77% 1,963,382 $1.31 $1.31 $1.19
    20 Mar 2026 $1.33 $-0.03 -2.20% 661,267 $1.37 $1.38 $1.33
    19 Mar 2026 $1.37 $-0.03 -2.15% 2,105,928 $1.42 $1.42 $1.34

    Director Transactions Data provided by Morningstar.

    Data provided by Morningstar.
    Date Director Type Amount Value Notes
    24 Mar 2026 Rohan Hockings Buy 82,550 $99,883
    On-market trade.
    06 Mar 2026 Rohan Hockings Issued 80,010 $120,015
    Rights issue.
    06 Mar 2026 Ian Constable Issued 123,000 $184,500
    Rights issue.
    23 Dec 2025 Peter Coleman Issued 2,000,000 $3,120,000
    Director remuneration.
    26 Nov 2025 Rohan Hockings Buy 133,350 $200,003
    On-market trade.

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Professor Ian Jeffrey Constable Non-Executive Director Sep 2025
    Professor Constable was the Foundation Lions Professor of Ophthalmology at the University of Western Australia, Foundation Chair of the Australian Association of Ophthalmology and Visual Science, and Founding Managing Director of the Lions Eye Institute Limited. Professor Constable is a member of the Advisory Board of the Lowy Medical Research Institute based in San Diego and Chair of the Scientific Advisory board of the Snow Vision Accelerator. US based Directors.
    Mr Peter John Coleman Non-Executive ChairmanNon-Executive Director Nov 2025
    Mr Coleman previously served as the CEO of Woodside between 2011 and 2021 and brings experience across both commercial and corporate governance domains with particular expertise in corporate and asset-level mergers and acquisitions.
    Dr Rohan Hockings Chief Executive OfficerManaging Director Aug 2016
    Dr Hockings spent four years with McKinsey & Company and a further two years in the Private Equity industry before joining PYC Therapeutics. He is a founding principal of a private equity fund active in the acquisition of health care assets within Australia. His previous roles include strategy and operational advisory positions with a global management consulting firm, equity capital markets experience as a solicitor with a national law firm and several appointments as a medical practitioner.
    Mr Daniel Coletta Joint Company Secretary Mar 2026
    -
    Daniel Coletta Joint Company Secretary
    -

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    Australian Land Pty Ltd <The Southdown A/C> 76,568,655 13.13%
    Hsbc Custody Nominees (Australia) Limited 48,518,521 8.32%
    Citicorp Nominess Pty Limited 34,134,159 5.85%
    Mccusker Holdings Pty Ltd 23,258,000 3.99%
    Pagham Pty Ltd <The Aintree A/C> 22,574,796 3.87%
    Runcton Pty Ltd <The Goodwood A/C> 22,574,796 3.87%
    Stockbridge Corporation Pty Ltd <The Ascot A/C> 22,574,796 3.87%
    Trexon Pty Ltd Blackpool Trust A/C> 22,574,796 3.87%
    J P Morgan Nominees Australia Pty Limited 19,179,605 3.29%
    Sietsma Holdings Pty Ltd <The Sietsma Super Fund A/C> 16,875,000 2.89%
    National Nominees Limited 15,025,437 2.58%
    Australian Land Pty Ltd <The Tribe Super Fund A/C> 11,313,636 1.94%
    Datamatch Pty Ltd <Paragon Family A/C> 9,000,000 1.54%
    Mr Adrian Bonaddio 8,249,561 1.41%
    Mr John Baird 6,400,266 1.10%
    Masali Pty Ltd 5,334,329 0.91%
    Locca Pty Ltd 5,209,172 0.89%
    Mr Adam Bonaddio 5,002,069 0.86%
    Selwood Barton Pty Ltd <Selwood Barton A/C> 4,820,000 0.83%
    Mccusker Foundation Ltd <The Mccusker Charitable A/C> 4,200,000 0.72%

    Profile

    since

    Note